<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580655</url>
  </required_header>
  <id_info>
    <org_study_id>BLU-285-2202</org_study_id>
    <secondary_id>2017-004836-13</secondary_id>
    <nct_id>NCT03580655</nct_id>
  </id_info>
  <brief_title>(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis</brief_title>
  <official_title>An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blueprint Medicines Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blueprint Medicines Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of
      avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including
      patients with aggressive SM (ASM), SM with associated hematologic neoplasm (SM-AHN), and mast
      cell leukemia (MCL)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2018</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) based on modified International Working Group-Myeloproliferative Neoplasms Research and Treatment and European Competence Network on Mastocytosis (IWG-MRT-ECNM) response criteria</measure>
    <time_frame>10 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Advanced Systemic Mastocytosis-Symptom Assessment Form (AdvSM-SAF) Total Symptom Score</measure>
    <time_frame>10 Months</time_frame>
    <description>0 - 80 points (higher value represents worse symptom outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Approximately 4 years after the first subjected enrolled</time_frame>
    <description>Including morphologic complete remission (mCR), morphologic CR with partial recovery of peripheral blood (mCRh), and morphologic partial remission (mPR) based on Pure Pathologic Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-response (TTR)</measure>
    <time_frame>10 Months</time_frame>
    <description>Months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>10 Months</time_frame>
    <description>Months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>10 Months</time_frame>
    <description>Months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>10 Months</time_frame>
    <description>Months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in bone marrow mast cells</measure>
    <time_frame>10 Months</time_frame>
    <description>percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum tryptase</measure>
    <time_frame>10 Months</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog aspartate 816 valine (KIT D816V) mutation burden</measure>
    <time_frame>10 Months</time_frame>
    <description>percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in liver volume by imaging</measure>
    <time_frame>10 Months</time_frame>
    <description>mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in spleen volume by imaging</measure>
    <time_frame>10 Months</time_frame>
    <description>mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit based on modified IWG-MRT-ECNM consensus criteria</measure>
    <time_frame>10 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PGIS</measure>
    <time_frame>10 Months</time_frame>
    <description>0 - 10 points (higher value represents worse symptom outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EORTC QLQ-C30</measure>
    <time_frame>10 Months</time_frame>
    <description>0 - 100 points (lower value represents worse quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Avapritinib as assessed by incidence of adverse events</measure>
    <time_frame>10 Months</time_frame>
    <description>CTCAE version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (0 to Tau) for Avapritinib</measure>
    <time_frame>4 Months</time_frame>
    <description>h•ng/mL</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">103</enrollment>
  <condition>Advanced Systemic Mastocytosis</condition>
  <condition>Aggressive Systemic Mastocytosis</condition>
  <condition>Systemic Mastocytosis With an Associated Hematologic Neoplasm</condition>
  <condition>Mast Cell Leukemia</condition>
  <arm_group>
    <arm_group_label>Avapritinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avapritinib will be administered as an immediate release tablet, orally, continuously, in 28-day cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avapritinib</intervention_name>
    <description>Avapritinib tablet</description>
    <arm_group_label>Avapritinib</arm_group_label>
    <other_name>BLU-285</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Patient must have a diagnosis of aggressive systemic mastocytosis (ASM), systemic
             mastocytosis with an associated hematologic neoplasm (SM-AHN) or mast cell leukemia
             (MCL) based on World Health Organization diagnostic criteria. Before enrollment, the
             Study Steering Committee must confirm the diagnosis of AdvSM (based on Central
             Pathology Laboratory assessment of bone marrow).

          2. Patient must have a serum tryptase ≥ 20 ng/mL.

          3. Patient must have Eastern Cooperative Oncology Group (ECOG) performance status (PS) of
             0 to 3.

        Key Exclusion Criteria:

          1. Patient has received prior treatment with avapritinib.

          2. Patient has received any cytoreductive therapy (including midostaurin and other TKIs,
             hydroxyurea, azacitidine) or an investigational agent less than 14 days, and for
             cladribine, interferon alpha, pegylated interferon and any antibody therapy (eg,
             brentuximab vedotin) less than 28 days before obtaining screening BM biopsy for this
             study.

          3. Patient has eosinophilia and known positivity for the FIP1L1 PGDFRA fusion, unless the
             patient has demonstrated relapse or PD on prior imatinib therapy. Patients with
             eosinophilia (&gt; 1.5 × 10^9/L), who do not have a detectable KIT D816 mutation, must be
             tested for a PDGFRA fusion mutation by fluorescence in situ hybridization (FISH) or
             polymerase chain reaction (PCR).

          4. Patient has history of another primary malignancy that has been diagnosed or required
             therapy within 3 years before the first dose of study drug. The following are exempt
             from the 3-year limit: completely resected basal cell and squamous cell skin cancer,
             curatively treated localized prostate cancer, and completely resected carcinoma in
             situ of any site.

          5. Patient has a QT interval corrected using Fridericia's formula (QTcF) &gt; 480 msec.

          6. Patient has a known risk or recent history (12 months before the first dose of study
             drug) of intracranial bleeding (eg, brain aneurysm, concomitant vitamin K antagonist
             use).

          7. Platelet count &lt; 50,000/μL (within 4 weeks of the first dose of study drug) or
             receiving platelet transfusion(s).

          8. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;3 x the upper
             limit of normal (ULN); no restriction if due to suspected liver infiltration by mast
             cells.

          9. Bilirubin &gt;1.5 × ULN; no restriction if due to suspected liver infiltration by mast
             cells or Gilbert's disease. (In the case of Gilbert's disease, a direct bilirubin &gt;2 ×
             ULN would be an exclusion.)

         10. Estimated glomerular filtration rate (eGFR) &lt; 30 mL/min/1.73m2 or creatinine &gt; 1.5 ×
             ULN.

         11. Patient has a primary brain malignancy or metastases to the brain.

         12. Patient has a history of a seizure disorder (eg, epilepsy) or requirement for
             antiseizure medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Blueprint Medicines</last_name>
    <phone>617-714-6707</phone>
    <email>medinfo@blueprintmedicines.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jason Gotlib, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Celalettin Ustun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Abdulraheem Yacoub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel J. DeAngelo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kristen Pettit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephen Oh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark L. Heaney, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elizabeth O. Hexner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas, MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prithviraj Bose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mays Cancer Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ruben A. Mesa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Deininger, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lisa Hicks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital, Department of Haematology</name>
      <address>
        <city>Odense</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hanne Vestergaard, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier Hermine, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Hôpital Larrey</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cristina Livideanu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen, Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltranslplantation</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jens Peter Panse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf, Zentrum für Onkologie</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Schafhausen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig, Medizinische Klinik und Poliklinik I - Hämatologie und Zelltherapie, lnternistische Onkologie, Hämostaseologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Uwe Platzbecker, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim III. Medizinische Klinik</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andreas Johannes Reiter, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der TU München</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philipp Jost, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi, CRIMM - Centro di Ricerca ed Innovazione per le Malattie Mieloproliferative</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alessandro Vannucchi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. OO.RR. S.Giovanni di Dio e Ruggi d'Aragona, University of Salerno</name>
      <address>
        <city>Salerno</city>
        <zip>84131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Massimo Triggiani, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen (UMCG)</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lambert Span, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital-Rikshospitalet, Hematology</name>
      <address>
        <city>Oslo</city>
        <zip>0372</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ingunn Dybedal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrzej Mital, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu, Klinice Hematologii, Nowotworów Krwi i Transplantacji Szpiku</name>
      <address>
        <city>Wrocław</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tomasz Wrόbel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>lnstituto de Estudios de Mastocitosis de Castilla la Mancha, Hospital Virgen del Valle - Complejo Hospitalario de Toledo</name>
      <address>
        <city>Toledo</city>
        <zip>45071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Iván Alvarez-Twose, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Drummond, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Deepti H. Radia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://PathfinderTrial.com</url>
    <description>More information about the study</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 3, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastocytosis</mesh_term>
    <mesh_term>Mastocytosis, Systemic</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Leukemia, Mast-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

